Unknown

Dataset Information

Blocking α<sub>4</sub>β<sub>7</sub> integrin delays viral rebound in SHIV<sub>SF162P3</sub>-infected macaques treated with anti-HIV broadly neutralizing antibodies.


ABSTRACT: Anti-HIV broadly neutralizing antibodies (bNAbs) may favor development of antiviral immunity by engaging the immune system during immunotherapy. Targeting integrin α4β7 with an anti-α4β7 monoclonal antibody (Rh-α4β7) affects immune responses in SIV/SHIV-infected macaques. To explore the therapeutic potential of combining bNAbs with α4β7 integrin blockade, SHIVSF162P3-infected, viremic rhesus macaques were treated with bNAbs only (VRC07-523LS and PGT128 anti-HIV antibodies) or a combination of bNAbs and Rh-α4β7 or were left untreated as a control. Treatment with bNAbs alone decreased viremia below 200 copies/ml in all macaques, but seven of eight macaques (87.5%) in the b

SUBMITTER: Frank I 

PROVIDER: S-EPMC8977869 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature